Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Arecor Therapeutics PLC ( (GB:AREC) ) is now available.
Arecor Therapeutics plc announced that its CEO, Sarah Howell, and CFO, David Ellam, will present the company’s final results for the year ended 31 December 2024 on the Investor Meet Company platform on 1 May 2025. This presentation is accessible to both existing and potential shareholders, allowing them to submit questions in advance or during the live session. This initiative reflects Arecor’s commitment to transparency and engagement with its stakeholders, potentially enhancing its market presence and investor relations.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a globally focused biopharmaceutical company dedicated to transforming patient care by bringing innovative medicines to market. The company enhances existing therapeutic products through its proprietary technology platform, Arestat™, and develops a portfolio of proprietary products in diabetes and other indications. Arecor collaborates with leading pharmaceutical and biotechnology companies to deliver therapeutic products, supported by an extensive patent portfolio.
YTD Price Performance: -48.30%
Average Trading Volume: 19,257
Technical Sentiment Signal: Buy
Current Market Cap: £14.35M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.